Press Release

Pharmacia and KAKEN Revise Copromotion Agreement for Cytotec, a Drug for NSAID-induced UlcersDecember 17, 2001

 Pharmacia K.K. ( headquarters: Shinjuku-ku, Tokyo; president: Lawrence J. Payne ) and KAKEN PHARMACEUTICAL CO., LTD. ( headquarters: Bunkyo-ku, Tokyo; president: Shiro Inui ) announced today that they have reached a basic agreement to revise their copromotion agreement for Cytotec 100 and 200 Tablets ( generic name: misoprostol ), a drug for ulcers caused by NSAIDs, to allow KAKEN to market the products alone from January 1, 2002. At present, the two companies copromote the products using a common brand name.

 

 Pharmacia and KAKEN started comarketing in 1995 and switched to copromotion in June 1998. Copromotion will be continued until December 31, 2001.

 

 Cytotec is a prostaglandin E1 derivative synthesized by G.D.Searle ( currently Pharmacia Corporation; headquarters, New Jersey, US; chairman and CEO, Fred Hassan ) . It is an anti-ulcer drug which not only suppresses gastric acid secretion but also protects the gastric mucosa ( cytoprotection ). It shows good healing effects on gastric and duodenal ulcers caused by long-term administration of non-steroidal anti-inflammatory drugs ( NSAID ). Cytotec 200 Tablets and Cytotec 100 Tablets were launched in March 1993 and December 1996, respectively.

Back to list